Abstract
As we continue to understand more about the complex mechanism of growth, a plethora of novel therapies have recently been developed that aim to address barriers and optimize efficacy. This review aims to explore these novel therapies and provide a succinct review based on the latest clinical studies in order to introduce clinicians to therapies that will soon constitute the future in the field of short stature. Conclusion: The review focuses on long-acting growth hormone formulations, a novel growth hormone oral secretagogue, novel treatments for children with achondroplasia, and targeted therapies for rare forms of skeletal dysplasias. (Table presented.)
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1121-1128 |
| Number of pages | 8 |
| Journal | European Journal of Pediatrics |
| Volume | 183 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2024 |
| Externally published | Yes |
Keywords
- Achondroplasia
- Burosumab Carbamazepine
- CNP
- Growth hormone (GH)
- Growth hormone deficiency
- IGF-1
- Infigratinib
- Lonapegsomatropin
- Long-acting GH
- LUM201
- Short stature
- Somapacitan
- Somatrogon
- TransCon CNP
- Vosoritide
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Fingerprint
Dive into the research topics of 'Novel therapies for growth disorders'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS